Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Молекулярно-биологические маркеры в химиотерапевтическом лечении метастатического рака толстой кишки
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М., 2005.
2. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). Пособие для врачей-онкологов. М., 2006; 128 с.
3. Переводчикова Н.И. Химиотерапия метастатического рака. Новое в терапии колоректального рака. М., 2001; с. 63–73.
4. Cassidy JS, Clarke E, Diaz-Rubio et al. XELOX compared to FOLFOX4: Survival and response results form XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patient with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4030.
5. De Anglis L, Posner J. Complication of Cancer and its Treatment. Neurologic Complications. In: Cancer Dedicine. 6th ed. Ed by J Holland, E. Frei III. BC Decker Inc. Hamolton London, 2003; p. 2451–67.
6. De Gramont A. Figer A, Seymour M et al. Leucovorin and fluorouracil with or whithout oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 200; 18: 2938–47.
7. Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as a singl agent in previously untreated colorectal carcinoma patients: A phase II multicentric trial. Ann Oncol 1998; 9: 105–8.
8. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicentrer randomized trial of oxaliplatin added to chronomodulated fluorouracol-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–47.
9. Goldberg R. Therapy for Metastatic Colorectal Cancer. Oncologist 2006; 11: 981–7.
10. Grem J, Uchida K, Salonga D et al. Thymidylate synthase, dihidropyrimidne dehydrogenase, ERCCl, and thymidine phosphorylase gene expression in primary and metastatic colorectal cancer tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. J Clin Oncol 2005; 23 (16S).
11. Ishitsuka H, Miwa M, Ishikawa T et al. Capcetabine: An orally available fluoropirimidine with tumor selective activity. Proc ASCO 1995; ab. 407.
12. Jakobsen A, Nielsen J, Gyldenderne N et al. Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal ATissue As Predictors of Fluorouracil Sensitivity. J Clin Oncol 2005; 23: 1365–9.
13. Kidani Y, Noji M, Tashiro T. Antitumor activity of Platinum (II) Complexes of 1,2-diaminocyclohexane isomers. Gann 1980; 71: 637–43.
14. Lenz H. Pharmacogenomics and colorectal cancer. Annals of Oncology 2004; 15 (4): 173–7.
15. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of Oxaliplatin (L-OHP) for treatment of patients with advanced colorectla carcinoma who resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95–8.
16. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihidropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracol tolerance. Mol Cancer Ther 2006; 5: 2895–904.
17. Ribelles N, Sanchez A, Lopez Siles J et al. Parmacogenetic study in patients with metastatic breast and colorectal cancer treated with Capecitabine. J Clin Oncol 2005; 23: 16S.
2. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). Пособие для врачей-онкологов. М., 2006; 128 с.
3. Переводчикова Н.И. Химиотерапия метастатического рака. Новое в терапии колоректального рака. М., 2001; с. 63–73.
4. Cassidy JS, Clarke E, Diaz-Rubio et al. XELOX compared to FOLFOX4: Survival and response results form XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patient with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4030.
5. De Anglis L, Posner J. Complication of Cancer and its Treatment. Neurologic Complications. In: Cancer Dedicine. 6th ed. Ed by J Holland, E. Frei III. BC Decker Inc. Hamolton London, 2003; p. 2451–67.
6. De Gramont A. Figer A, Seymour M et al. Leucovorin and fluorouracil with or whithout oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 200; 18: 2938–47.
7. Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as a singl agent in previously untreated colorectal carcinoma patients: A phase II multicentric trial. Ann Oncol 1998; 9: 105–8.
8. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicentrer randomized trial of oxaliplatin added to chronomodulated fluorouracol-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–47.
9. Goldberg R. Therapy for Metastatic Colorectal Cancer. Oncologist 2006; 11: 981–7.
10. Grem J, Uchida K, Salonga D et al. Thymidylate synthase, dihidropyrimidne dehydrogenase, ERCCl, and thymidine phosphorylase gene expression in primary and metastatic colorectal cancer tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. J Clin Oncol 2005; 23 (16S).
11. Ishitsuka H, Miwa M, Ishikawa T et al. Capcetabine: An orally available fluoropirimidine with tumor selective activity. Proc ASCO 1995; ab. 407.
12. Jakobsen A, Nielsen J, Gyldenderne N et al. Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphism in Normal ATissue As Predictors of Fluorouracil Sensitivity. J Clin Oncol 2005; 23: 1365–9.
13. Kidani Y, Noji M, Tashiro T. Antitumor activity of Platinum (II) Complexes of 1,2-diaminocyclohexane isomers. Gann 1980; 71: 637–43.
14. Lenz H. Pharmacogenomics and colorectal cancer. Annals of Oncology 2004; 15 (4): 173–7.
15. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of Oxaliplatin (L-OHP) for treatment of patients with advanced colorectla carcinoma who resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95–8.
16. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihidropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracol tolerance. Mol Cancer Ther 2006; 5: 2895–904.
17. Ribelles N, Sanchez A, Lopez Siles J et al. Parmacogenetic study in patients with metastatic breast and colorectal cancer treated with Capecitabine. J Clin Oncol 2005; 23: 16S.
Авторы
Е.А.Кузнецова, П.В.Еропкин, В.Н.Кашников
ФГУ ГНЦ Колопроктологии Росмедтехнологий, Москва
ФГУ ГНЦ Колопроктологии Росмедтехнологий, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.